SARS-CoV
As many as 60% of patients with SARS-CoV had myalgia with up to 30% presenting with muscle weakness and increased creatinine phosphokinase (Table 6).10 , 34 , 117, 118, 119 However, there was no statistically significant difference in creatinine phosphokinase levels between SARS-CoV patients with ARDS vs. patients without ARDS.117 Muscle weakness was typically symmetric and involves truncal and weakness of the proximal limbs and neck muscles with sparing of the facial and small hand muscles.119 Muscle atrophy may also be the result of steroid myopathy or critical illness myopathy 119 A variable degree of focal myofibril necrosis noted postmortem without evidence of viral particles suggests that muscle damage is likely the result of immune-mediated damage.119 Cutaneous manifestations of SARS-CoV hasn't yet been reported in the literature to the authors’ knowledge.